- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05243810
EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers
EPC Silver Wound Gel (EPC-123) Feasibility Clinical Study: Prospective, Single-arm, Repeated Measures Study of EPC Silver Wound Gel in the Management of Locally Infected Diabetic Foot Ulcers
Study Overview
Status
Intervention / Treatment
Detailed Description
The objective of the proposed work is 1) to monitor clinical safety of EPC Silver Wound Gel on diabetic foot ulcers, 2) to evaluate the clinical impact of EPC Silver Wound Gel in foot ulcer progression in conjunction with the standard of care 3) to quantify the changes within the wound bacterial environment as it impacts wound healing and 4) to evaluate subjective patient and clinician outcomes: satisfaction, quality of life, perceived benefit, and compliance.
Consenting subjects who qualify for enrollment will proceed with two, weekly, visits related to screening. If screen passed, ie. under the current standard of care no progression of the diabetic foot ulcer is observed in accordance with validated diabetic foot ulcer classification metrics, then the subject will proceed with two weeks of study period where twice weekly clinic and twice weekly intermediate home-based care. This may be followed by an additional two weeks of study period, if warranted in accordance with best practice, with once weekly clinic and intermediate home care visits. In total there will be up to 9 clinic visits (minimum 7 clinic visits up to 9 clinic visits) in 6 weeks (screening and trial visits; minimum 4 weeks up to a maximum of 6 weeks).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6C0A7
- Lawson Health Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with diabetes mellitus according to definitions outlined by the American Diabetes Association
- Presenting with an active or current foot ulcer that has been identified as stalled or persistent non-healing under current standard-of-care; showing no progression in 2 weeks as per IDSA guidelines.
- Presenting with a localized mild or local infection of the ulcer as listed in the IWGDF/IDSA Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections (Table 1); exceeding 0.5 cm2 in area after appropriate debridement.
- Subject must agree to adhere to all protocol procedures and must be willing and able to provide written informed consent.
- Correction or optimization of underlying medical problems (e.g. diabetes or systemic infection).
Exclusion Criteria:
- Participants exhibiting extensive gangrene, and/or immediately limb-threatening infection
- Indications of osteomyelitis identified by plain radiographs taken within 2 days prior to study entry.
- No palpable dorsalis pedis or posterior tibial pulse or a pedal systolic pressure (Doppler ultrasound) of ≤ 40 mm Hg
- Clinically significant peripheral arterial disease requiring vascular intervention
- Patients requiring renal dialysis, immunosuppressive mediation, or those with uncontrolled hypertension.
- Lymphangitis; spread beneath the fascia; muscle, joint, or bone involvement.
- IDSA-defined severe infection, including systemic toxicity or metabolic instability
- Current use of enzymatic debridement.
- Participants with known silver sensitivity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
A prospective, single-arm, repeated measures feasibility study will be coordinated on the use of EPC Silver Wound Gel in patients with diabetic foot ulcers and localized infections within an outpatient clinical setting, to determine the safety of EPC Silver Wound Gel on diabetic foot ulcerations and impact on wound infection classification, wound ecology, and immunological biomarkers, in conjunction with the standard of care, to clarify parameters for a potential future study.
|
Re-application of EPC-123 will occur within 48 hours of the initial application.
Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M).
Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care.
To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of intervention-related adverse events collected throughout the trial
Time Frame: Up to 28 days
|
Clinical and/or biological adverse events will be reported over the intervention period.
Severity of any adverse events will be graded.
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Qualitative improvement in quality of life assessment during the intervention period compared with screening period under standard of care.
Time Frame: Up to 28 days
|
Quality of life will be assessed using the qualitative "Wound QoL" tool during the intervention period compared with qualitative assessment at baseline.
|
Up to 28 days
|
Progression of the Infectious Diseases Society of America and International Working Group on the Diabetic Foot Classifications of Diabetic Foot Infection during the intervention period compared with screening period under standard of care.
Time Frame: Up to 42 days
|
Progressions of PEDIS (grade 1 = no symptoms or signs of infection; to grade 4, local infection with the signs of systemic inflammatory response syndrome) or IDSA Infection Severity (Uninfected; to Severe) during the intervention period compared with screening period under standard of care.
|
Up to 42 days
|
Progression the Diabetic Foot Infection (DFI) Wound Score during the intervention period compared with screening period under standard of care.
Time Frame: Up to 42 days
|
Signs and symptoms of infection will be assessed using the 10-item DFI Wound Score system inclusive of semi-quantitative measurement of purulent discharge, non-purulent discharge, erythema, induration, tenderness, pain, warmth, size, depth, undermining.
The DFI Wound Score ranges from a score of 3 (less severe wound) to 49 (more severe wound).
Rate of change in DFI score during the intervention period will be compared with screening period under standard of care.
|
Up to 42 days
|
Progression the Bioburden Assessment Tool (BAT) during the intervention period compared with screening period under standard of care.
Time Frame: Up to 42 days
|
The degree of bioburden will be assessed using BAT; measuring for the presence or absence of signs and symptoms of infection and bioburden and subsequent clinical interpretation.
Progressions of the level of bioburden risk, from Category I (colonized: at risk) to Category VI (systemic infection), during the intervention period will be compared with screening period under standard of care.
|
Up to 42 days
|
Early clinical response
Time Frame: Within 48-72 hours of first intervention application
|
Quantitation of lesion erythema area and wound area at 48-72 hours following the first intervention application.
|
Within 48-72 hours of first intervention application
|
Number of participants with systemic antibiotic or antifungal drug administration over the course of the intervention versus screening and baseline.
Time Frame: Up to 42 days
|
Report on the number of participants receiving administration of systemic antibiotic or antifungal drugs during the intervention period compared with screening period under standard of care.
|
Up to 42 days
|
Progression in the absolute number of critical or qualified pathogen species present within the wound microbiome over the course of the intervention versus screening and baseline.
Time Frame: Up to 42 days
|
Progression in the absolute number of critical or qualified pathogens (inclusive of those pathogens identified by the Centre for Disease Control and Prevention, World Health Organization, and the FDA as per 79 FR 32464) as per gene pyrosequencing over the course of intervention versus screening and baseline.
|
Up to 42 days
|
Progression in the relative quantity of critical or qualified pathogens versus commensal organisms present within the wound microbiome over the course of the intervention versus screening and baseline.
Time Frame: Up to 42 days
|
Progression in the relative composition of critical or qualified pathogens (inclusive of those pathogens identified by the Centre for Disease Control and Prevention, World Health Organization, and the FDA as per 79 FR 32464) versus commensal organisms in the wound microbiome of as per gene pyrosequencing over the course of intervention versus screening and baseline.
|
Up to 42 days
|
Progression in wound microbiome over the course of the intervention versus screening and baseline.
Time Frame: Up to 42 days
|
Progression of the wound microbiome on a whole ecology basis as per gene pyrosequencing; evaluating for community membership, structure, and diversity over the course of intervention versus screening and baseline.
|
Up to 42 days
|
Percent change in wound area and volume during the intervention period compared to baseline.
Time Frame: Up to 28 days
|
Percent change in wound volume (cm3) at each visit compared to baseline.
|
Up to 28 days
|
Rate of wound closure, specifically percent change in area, during the intervention period compared with screening period under standard of care.
Time Frame: Up to 42 days
|
Rate of wound closure, change in wound area (cm2), over the course of the intervention period compared to the screening period.
|
Up to 42 days
|
Rate of wound closure, specifically percent change in volume, during the intervention period compared with screening period under standard of care.
Time Frame: Up to 42 days
|
Rate of wound closure, change in wound volume (cm3), over the course of the intervention period compared to the screening period.
|
Up to 42 days
|
Qualitative evaluation of patient satisfaction via questionnaire.
Time Frame: Up to 28 days
|
Patient satisfaction over the course of the intervention period will evaluated.
Patient satisfaction of the performance of the intervention will be evaluated within a rating scale of "poor" through to "excellent".
|
Up to 28 days
|
Qualitative evaluation of clinician satisfaction via questionnaire.
Time Frame: Up to 28 days
|
Clinician satisfaction over the course of the intervention period will evaluated.
Clinician satisfaction of the performance of the intervention will be evaluated within a rating scale of "poor" through to "excellent".
|
Up to 28 days
|
Progression of systemic biomarker C-Reactive protein (CRP).
Time Frame: Up to 28 days
|
Quantitation of clinical change in CRP (mg/L) from baseline to end of intervention period.
|
Up to 28 days
|
Progression of systemic biomarker Erythrocyte sedimentation rate (ESR).
Time Frame: Up to 28 days
|
Quantitation of clinical change in ESR (mm/hr) from baseline to end of intervention period.
|
Up to 28 days
|
Progression of systemic biomarker CBC and Differential.
Time Frame: Up to 28 days
|
Quantitation of clinical change in CBC and Differential (cells per cubic millimeter) from baseline to end of intervention period.
|
Up to 28 days
|
Progression of systemic biomarker body temperature.
Time Frame: Up to 42 days
|
Quantitation of clinical change in body temperature (degree Celsius) over the course of the intervention versus screening and baseline.
|
Up to 42 days
|
Progression in peri-wound microbiome over the course of the intervention versus screening and baseline.
Time Frame: Up to 42 days
|
Progression of the peri-wound microbiome on a whole ecology basis as per gene pyrosequencing; evaluating for community membership, structure, and diversity over the course of intervention versus screening and baseline.
|
Up to 42 days
|
Quantitative progression of local inflammatory biomarkers over the course of the intervention versus screening and baseline.
Time Frame: Up to 42 days
|
Quantitation of host inflammatory cytokines and chemokines (pg/ml) inclusive of: IL-1, IL-6, IL-8, IL-10 TNF-α, MMP-8, MMP-9, MMP-2, TIMP1, and TIMP2; within the wound over the course of the intervention versus screening and baseline.
|
Up to 42 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Blome C, Baade K, Debus ES, Price P, Augustin M. The "Wound-QoL": a short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. Wound Repair Regen. 2014 Jul-Aug;22(4):504-14. doi: 10.1111/wrr.12193.
- Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012 Jun;54(12):e132-73. doi: 10.1093/cid/cis346.
- Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020 Mar 24;13(1):16. doi: 10.1186/s13047-020-00383-2.
- Boulton AJM, Armstrong DG, Hardman MJ, Malone M, Embil JM, Attinger CE, Lipsky BA, Aragon-Sanchez J, Li HK, Schultz G, Kirsner RS. Diagnosis and Management of Diabetic Foot Infections. Arlington (VA): American Diabetes Association; 2020 Jan. Available from http://www.ncbi.nlm.nih.gov/books/NBK554227/
- Lipsky BA, Polis AB, Lantz KC, Norquist JM, Abramson MA. The value of a wound score for diabetic foot infections in predicting treatment outcome: a prospective analysis from the SIDESTEP trial. Wound Repair Regen. 2009 Sep-Oct;17(5):671-7. doi: 10.1111/j.1524-475X.2009.00521.x. Epub 2009 Aug 11.
- Lipsky BA, Senneville E, Abbas ZG, Aragon-Sanchez J, Diggle M, Embil JM, Kono S, Lavery LA, Malone M, van Asten SA, Urbancic-Rovan V, Peters EJG; International Working Group on the Diabetic Foot (IWGDF). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3280. doi: 10.1002/dmrr.3280.
- Houghton PE, Kincaid CB, Campbell KE, Woodbury MG, Keast DH. Photographic assessment of the appearance of chronic pressure and leg ulcers. Ostomy Wound Manage. 2000 Apr;46(4):20-6, 28-30.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR-0279
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
-
King Hamad University Hospital, BahrainUniversity of StellenboschWithdrawnDiabetic Foot Ulcer | Ulcer Foot
Clinical Trials on EPC Silver Wound Gel
-
HealthPartners InstituteCompletedD001458 | D011247United States
-
Coloplast A/SRecruitingPartial-thickness BurnUnited Kingdom
-
Lavior Pharma Inc.RecruitingDiabetic Foot UlcerUnited States
-
Primex ehfVizera d.o.o.; University of Ljubljana, Faculty of PharmacyRecruitingDiabetic Foot Ulcer | Venous Leg Ulcer | Pressure UlcerSlovenia
-
B. Braun Ltd. Centre of Excellence Infection ControlCompletedVenous Leg UlcerUnited Kingdom
-
Rochal Industries LLCThe University of Texas Health Science Center at San Antonio; Brooke Army Medical... and other collaboratorsNot yet recruiting
-
B. Braun Medical Inc.TerminatedWound of Lower Leg (Physical Finding)United States
-
University Hospital, LinkoepingCompleted
-
The University of Hong KongRecruiting
-
Madigan Army Medical CenterUnknownNormal SubjectsUnited States